Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Biliary Cancers
NCT00553332Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in biliary tract cancer (BTC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 8 weeks. Started Nov 2007; status: completed.
02
Drugs
selumetinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00553332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553332.